APOE and amyloidosis: Given that middle-aged and older APOE-ε4 carriers, on average, have more AD-related pathology than non-carriers due to an earlier onset of amyloid accumulation [55, 56], these results suggest that individuals with higher levels of CR may be better able to tolerate early AD-related brain changes.